Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02296645 · ClinicalTrials.gov registry record · Phase 2

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)

A Phase 2 study of Surgical Site Infection, sponsored by Zurex Pharma.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT02296645 is a Phase 2 study of Surgical Site Infection that has completed, run by Zurex Pharma. The registered enrollment target is 36 participants, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02296645, a Phase 2 study of Surgical Site Infection, has completed, sponsored by Zurex Pharma.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, paired-comparisons design where each subject receives two of the planned treatments.

Conditions Studied

Interventions

  • DRUG ZuraPrep
  • DRUG ChloraPrep

Study Locations (1)

Virginia

  • MicroBioTest Laboratories - Sterling

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2014-11
Est. Completion 2015-01
Phase Phase 2

Sponsor

Zurex Pharma

9 total trials

What the Registry Record Tells You About NCT02296645

The ClinicalTrials.gov registry entry for NCT02296645 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (94% lower). The listed sponsor is Zurex Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Surgical Site Infection appearing as the primary indexed condition, and to 2 interventions - of which ZuraPrep is the first listed.

NCT02296645 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT02296645 about?

NCT02296645 is a clinical study titled "Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)". This is a randomized, paired-comparisons design where each subject receives two of the planned treatments.

What is the current status of trial NCT02296645?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-11. Estimated completion is 2015-01.

What conditions does trial NCT02296645 study?

This clinical trial studies the following conditions: Surgical Site Infection.

What interventions are being tested in trial NCT02296645?

The interventions under investigation include: ZuraPrep (DRUG), ChloraPrep (DRUG).

Who is sponsoring clinical trial NCT02296645?

This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02296645 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgical Site Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.